| Original language | English (US) |
|---|---|
| Pages (from-to) | 1540-1554 |
| Number of pages | 15 |
| Journal | Infection Control and Hospital Epidemiology |
| Volume | 44 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 22 2023 |
ASJC Scopus subject areas
- Epidemiology
- Microbiology (medical)
- Infectious Diseases
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Infection Control and Hospital Epidemiology, Vol. 44, No. 10, 22.10.2023, p. 1540-1554.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Executive Summary
T2 - A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute-Care Hospitals: 2022 Updates
AU - Yokoe, Deborah S.
AU - Advani, Sonali D.
AU - Anderson, Deverick J.
AU - Babcock, Hilary M.
AU - Bell, Michael
AU - Berenholtz, Sean M.
AU - Bryant, Kristina A.
AU - Buetti, Niccolò
AU - Calderwood, Michael S.
AU - Calfee, David P.
AU - Dubberke, Erik R.
AU - Ellingson, Katherine D.
AU - Fishman, Neil O.
AU - Gerding, Dale N.
AU - Glowicz, Janet
AU - Hayden, Mary K.
AU - Kaye, Keith S.
AU - Klompas, Michael
AU - Kociolek, Larry K.
AU - Landon, Emily
AU - Larson, Elaine L.
AU - Malani, Anurag N.
AU - Marschall, Jonas
AU - Meddings, Jennifer
AU - Mermel, Leonard A.
AU - Patel, Payal K.
AU - Perl, Trish M.
AU - Popovich, Kyle J.
AU - Schaffzin, Joshua K.
AU - Septimus, Edward
AU - Trivedi, Kavita K.
AU - Weinstein, Robert A.
AU - Maragakis, Lisa L.
N1 - Funding Information: CAUTI section: S.A. reports consulting fees with IDSA, bioMerieux, Locus Biosciences, and GSK, and participation on a bioMerieux Advisory Board, and is co-owner of IPEC Experts, LLC. J.M. reports grant funding from the AHRQ, the CDC, the Ralph E. Wilson Foundation, and the VA HSR&D. All other authors report no conflicts of interest related to this article. Funding Information: MRSA section: A.M. received a research grant from Merck. A.H. served as an advisory and consultant for Cubist, UpToDate, and Premier, Inc. S.H. led a clinical trial in which participating hospitals received contributed product from Sage Products, Inc. J.M. conducted a clinical trial in which participating hospitals received contributed product from Sage Products, Inc. All other authors report no conflicts of interest related to this article. Funding Information: CLABSI section: N.B. received Mobility grants from the Swiss National Science Foundation (grant nos. P400PM_183865 and P4P4PM_194449) and a grant from the Bangerter-Rhyner Foundation. J.M. is the recipient of a project grant on surgical-site infections from the Swiss National Science Foundation (grant no. 32003B_179500, “Understanding the drivers of surgical site infection: Investigating and modeling the Swissnoso surveillance data”). L.M. served as an advisor and consultant to Marvao Medical Devices, Pristine Access Technologies, and Citius Pharma. L.H. served as an advisor and consultant to B Braun Medical, BD Medical, Atrion Medical, Nexus Medical, Teleflex. M.E.R. served as an advisor and consultant to 3M, Becton Dickinson, and Cetius, and Teleflex, and received honoraria from Teleflex. All other authors report no conflicts of interest related to this article. Funding Information: Hand hygiene section: A.A. reported payment from the analysis group for an expert presentation on litigation for prevention of infection in the community setting. K.H. reported consulting for Medillum and Nozin, a grant from the NC Department of Public Health, and providing a lecture for PDI. R.O. reported consulting for Specified Technologies and Northshore University Health System, providing expert testimony for Saxton & Stump, providing a lecture for the Teleflex Medical Advisory Board, providing subject-matter expertise for APIC for AHA HRET, and performing peer review of a manuscript for Joint Commission Resources. All other authors report no conflicts of interest related to this article. Funding Information: Expert Panel: H.M.B. reports institutional funding from CDC for a Prevention Epicenter; K.A.B. is the PI for multicenter clinical trials funded for institution by Pfizer, Gilead, and Enanta; M.K.H. reports institutional funding from CDC for a Prevention Epicenter and from the Chicago Department of Public Health for a Regional Innovative Public Health Laboratory; R.A.W. is a paid reviewer for UpToDate. All other authors report no conflicts of interest related to this article. Funding Information: Financial support for the Compendium: 2022 Updates was provided by the Society for Healthcare Epidemiology of America (SHEA). Funding Information: Implementation section: K.K.T. is the owner of the consulting company Trivedi Consults, LLC. V.M.D. is the owner of the consulting company Youngtree Communications, LLC. R.C. has consulting relationships with Moderna, Novavax, and Pfizer (speakers bureau, research contract) and Sanofi (speakers bureau). M.L.S. has grant funding from 3M and PDI for nasal decolonization. All other authors report no conflicts of interest related to this article. Funding Information: VAP, VAE, NV-HAP section: M.K. has received grant funding from CDC and AHRQ plus royalties from UpToDate, Inc. R.B. has served as an advisor and consultant to Pfizer, Mallinckrodt, Ventec Life Systems, Vyaire and Zoll Medical. K.A.C. has received honoraria from BD, CloroxPro, and Elsevier. L.R.G. has received honoraria from Premier, Inc, Care Fusion, Infection Control Today, and Advanced Sterilization Products. All other authors report no conflicts of interest related to this article.
PY - 2023/10/22
Y1 - 2023/10/22
UR - http://www.scopus.com/inward/record.url?scp=85172796584&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85172796584&partnerID=8YFLogxK
U2 - 10.1017/ice.2023.138
DO - 10.1017/ice.2023.138
M3 - Article
C2 - 37606298
AN - SCOPUS:85172796584
SN - 0899-823X
VL - 44
SP - 1540
EP - 1554
JO - Infection Control and Hospital Epidemiology
JF - Infection Control and Hospital Epidemiology
IS - 10
ER -